949142-50-1
Post Buying Request-
-
Basic information
- Product Name: Afutuzumab
- Synonyms: afutuzumab;Ga 101;Humab(cd20);Ro 5072759;Ro5072759
- CAS NO:949142-50-1
- Molecular Formula:
- Molecular Weight: 0
- EINECS: N/A
- Product Categories: N/A
- Mol File: 949142-50-1.mol
- Article Data: 0
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: Afutuzumab(CAS DataBase Reference)
- NIST Chemistry Reference: Afutuzumab(949142-50-1)
- EPA Substance Registry System: Afutuzumab(949142-50-1)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 949142-50-1(Hazardous Substances Data)
949142-50-1 Suppliers
Recommended suppliersmore
949142-50-1 Usage
Description
Afutuzumab, also known as GA101 or obinutuzumab, is a glycoengineered, type II anti-CD20 antibody that was approved by the US FDA in November 2013 for the treatment of previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil chemotherapy. It is the first drug approved under the FDA’s breakthrough therapy designation, which was created in 2012 to expedite the development and review of drugs for serious conditions. The Fc portion of afutuzumab was glycoengineered to reduce fucosylation of the Fc carbohydrate, resulting in increased FcγRIIIa affinity and antibody-dependent cellular cytotoxicity (ADCC) potency.Used in Oncology:
Afutuzumab is used as a third-generation anti-CD20 antibody for the treatment of previously untreated chronic lymphocytic leukemia (CLL). It demonstrates lower complement-mediated cytotoxicity, more potent mediation of cell death via the nonclassical apoptosis pathway, and increased ADCC as compared with rituximab in preclinical studies. Additionally, afutuzumab induced a stronger antitumor effect in mouse xenograft models of human lymphoma than rituximab and ofatumumab, supporting its clinical investigation and use in oncology.
Originator
GlycArt Biotechnology AG (United States)Check Digit Verification of cas no
The CAS Registry Mumber 949142-50-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,9,1,4 and 2 respectively; the second part has 2 digits, 5 and 0 respectively.Calculate Digit Verification of CAS Registry Number 949142-50:
(8*9)+(7*4)+(6*9)+(5*1)+(4*4)+(3*2)+(2*5)+(1*0)=191
191 % 10 = 1
So 949142-50-1 is a valid CAS Registry Number.
949142-50-1Upstream product
949142-50-1Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 949142-50-1
Afutuzumab
